The KRAS mutation is found in several cancers such as pancreatic cancer, colorectal cancer, lung cancer, bile duct cancer and thyroid cancer. The existence of KRAS mutations is often associated with a prognostic marker of drug response. For example, the KRAS mutation is considered a strong prognostic marker for drug response to tyrosine kinase inhibitors such as Gefitinib (Iressa) or Erlotinib (Tarceva). Recently, KRAS mutation is often detected in colorectal cancer and may be related to drug response to Cetuximab (Erbitux) or Panitumumab (Vectibix) used for colon cancer therapy. Therefore, KRAS mutation testing is necessary to determine drug resistance in patients with colorectal or lung cancer and will be useful for anticancer therapies.
PANAMutyper™ R KRAS
To detect KRAS mutations and determine their response to various treatments in colon cancer.
Cat. No. PNAR-1001
Other products
EZ-10 spin column Total RNA Minipreps super kit (BS784-250PREPS)
Kit for rapid isolation of total RNA from various organisms....
PNAM-2001
Herpes simplex virus 1 Herpes simplex virus 2 48 test
Colorimetric ELISA Plates – CIH-F8T
CIH-F8T CIM-F8T Colorimetric ELISA Plates
Plant Total RNA Purification Kit (BS82314-50PREPS)
The EZ Spin Column Plant Total RNA Purification Kit is...